World-Class Experts Join Immuthera’s Scientific Advisory Board

We’re thrilled to welcome three worldclass leaders to the Scientific Advisory Board of Immuthera, a subsidiary of PolTREG

Dr. Jay Skyler – A pioneer of intensive insulin therapy, architect of NIH trials (DPT1, TrialNet), and founding EditorinChief of Diabetes Care.
Dr. Desmond Schatz – Champion of pediatric diabetes prevention and genetics (TEDDY, HIRN), with 400+ publications and decades of NIH/JDRF leadership.
Dr. Lawrence Steinman – Creator of Tysabri for MS, discoverer of the EBV–MS link, and trailblazer in antigenspecific and DNA vaccine therapies.

Over the coming months, we’ll continue to expand our SAB to build a truly worldclass team.

In partnership with PolTREG and top U.S. academic centers, we’re advancing a pipeline of cuttingedge, clinically validated Treg cell therapies for autoimmune and neuroinflammatory diseases.

“At Immuthera, we’re uniquely positioned to accelerate transformative therapies for type 1 diabetes and and other autoimmune diseases” – said Prof. Piotr Trzonkowski, CEO of Immuthera & PolTREG.

Read the full press release